tetano
Editor, Senior Moderator
Vaccine. 2016 Jun 16. pii: S0264-410X(16)30408-X. doi: 10.1016/j.vaccine.2016.06.009. [Epub ahead of print]
[h=1]Protective efficacy of an inactivated Eurasian avian-like H1N1 swine influenza vaccine against homologous H1N1 and heterologous H1N1 and H1N2 viruses in mice.[/h] Sui J[SUP]1[/SUP], Yang D[SUP]1[/SUP], Qiao C[SUP]2[/SUP], Xu H[SUP]1[/SUP], Xu B[SUP]1[/SUP], Wu Y[SUP]1[/SUP], Yang H[SUP]1[/SUP], Chen Y[SUP]1[/SUP], Chen H[SUP]3[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Eurasian avian-like H1N1 (EA H1N1) swine influenza viruses are prevalent in pigs in Europe and Asia, but occasionally cause human infection, which raises concern about their pandemic potential. Here, we produced a whole-virus inactivated vaccine with an EA H1N1 strain (A/swine/Guangxi/18/2011, SW/GX/18/11) and evaluated its efficacy against homologous H1N1 and heterologous H1N1 and H1N2 influenza viruses in mice. A strong humoral immune response, which we measured by hemagglutination inhibition (HI) and virus neutralization (VN), was induced in the vaccine-inoculated mice upon challenge. The inactivated SW/GX/18/11 vaccine provided complete protection against challenge with homologous SW/GX/18/11 virus in mice and provided effective protection against challenge with heterologous H1N1 and H1N2 viruses with distinctive genomic combinations. Our findings suggest that this EA H1N1 vaccine can provide protection against both homologous H1N1 and heterologous H1N1 or H1N2 virus infection. As such, it is an excellent vaccine candidate to prevent H1N1 swine influenza.
Copyright ? 2016 Elsevier Ltd. All rights reserved.
[h=4]KEYWORDS:[/h] Avian-like; H1N1; Swine influenza virus; Vaccine
PMID: 27321744 [PubMed - as supplied by publisher]
[h=1]Protective efficacy of an inactivated Eurasian avian-like H1N1 swine influenza vaccine against homologous H1N1 and heterologous H1N1 and H1N2 viruses in mice.[/h] Sui J[SUP]1[/SUP], Yang D[SUP]1[/SUP], Qiao C[SUP]2[/SUP], Xu H[SUP]1[/SUP], Xu B[SUP]1[/SUP], Wu Y[SUP]1[/SUP], Yang H[SUP]1[/SUP], Chen Y[SUP]1[/SUP], Chen H[SUP]3[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Eurasian avian-like H1N1 (EA H1N1) swine influenza viruses are prevalent in pigs in Europe and Asia, but occasionally cause human infection, which raises concern about their pandemic potential. Here, we produced a whole-virus inactivated vaccine with an EA H1N1 strain (A/swine/Guangxi/18/2011, SW/GX/18/11) and evaluated its efficacy against homologous H1N1 and heterologous H1N1 and H1N2 influenza viruses in mice. A strong humoral immune response, which we measured by hemagglutination inhibition (HI) and virus neutralization (VN), was induced in the vaccine-inoculated mice upon challenge. The inactivated SW/GX/18/11 vaccine provided complete protection against challenge with homologous SW/GX/18/11 virus in mice and provided effective protection against challenge with heterologous H1N1 and H1N2 viruses with distinctive genomic combinations. Our findings suggest that this EA H1N1 vaccine can provide protection against both homologous H1N1 and heterologous H1N1 or H1N2 virus infection. As such, it is an excellent vaccine candidate to prevent H1N1 swine influenza.
Copyright ? 2016 Elsevier Ltd. All rights reserved.
[h=4]KEYWORDS:[/h] Avian-like; H1N1; Swine influenza virus; Vaccine
PMID: 27321744 [PubMed - as supplied by publisher]